Apimeds Pharmaceuticals US, Inc.
APUSDrugs in Pipeline
2
Phase 3 Programs
1
Upcoming Catalysts
1
Next Catalyst
Next month
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
histamine
Osteoarthritis of the Knee
honeybee venom (Apitoxin (Korea) Apitox (USA))
Osteoarthritis of the Knee
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
histamine | Phase 3 | Osteoarthritis of the Knee | - | - |
honeybee venom (Apitoxin (Korea) Apitox (USA)) | Phase 2 | Osteoarthritis of the Knee | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Apimeds Pharmaceuticals US, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Apimeds Pharmaceuticals US, Inc.'s (APUS) pipeline across Phase 3, Phase 2. Its lead program is histamine (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Apimeds Pharmaceuticals US, Inc.'s next FDA catalyst?→
Apimeds Pharmaceuticals US, Inc.'s (APUS) next tracked catalyst is a Earnings expected November 11, 2026. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track APUS biotech catalysts?→
Add APUS to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Apimeds Pharmaceuticals US, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.